📗 Cite This Artifact
ambroxol-aspro-pd
Ambroxol ASPro-PD Trial (NCT05827068)
Overview
The Ambroxol ASPro-PD trial is an innovative Phase 2/3 clinical trial evaluating ambroxol, a mucolytic drug that has shown promise as a disease-modifying treatment for Parkinson's disease. This trial specifically focuses on ambroxol's ability to increase glucocerebrosidase (GCase) activity, addressing a key genetic pathway implicated in Parkinson's disease pathogenesis[@ambroxol2022][@gba2021].
Ambroxol represents a drug repurposing approach, taking advantage of an existing medication with a known safety profile to target a novel therapeutic pathway in Parkinson's disease. The ASPro-PD (Ambroxol Study in Parkinson's Disease) trial represents one of the most advanced efforts to bring a GCase-enhancing therapy to clinical application for Parkinson's disease patients[@ambroxol2024].
Trial Details
| Attribute | Value |
|-----------|-------|
| NCT Number | NCT05827068 |
| Phase | Phase 2/3 |
| Status | Active, Recruiting |
| Sponsor | University of Manchester / Parkinson's UK |
| Patient Population | Parkinson's disease with GBA1 variants or idiopathic PD |
| Duration | Approximately 2 years |
| Enrollment | Target 200 participants |
| Primary Endpoint | 24 months |
| Start Date | 2023 |
| Expected Completion | 2026 |
Treatment Arms
| Arm | Intervention | Dose | Route |
|-----|-------------|------|-------|
| 1 | Ambroxol | 1260 mg/day (split dosing) | Oral |
| 2 | Placebo | N/A | Oral |
| 3 | Ambroxol (extension) | 1260 mg/day | Oral |
Ambroxol ASPro-PD Trial (NCT05827068)
Overview
The Ambroxol ASPro-PD trial is an innovative Phase 2/3 clinical trial evaluating ambroxol, a mucolytic drug that has shown promise as a disease-modifying treatment for Parkinson's disease. This trial specifically focuses on ambroxol's ability to increase glucocerebrosidase (GCase) activity, addressing a key genetic pathway implicated in Parkinson's disease pathogenesis[@ambroxol2022][@gba2021].
Ambroxol represents a drug repurposing approach, taking advantage of an existing medication with a known safety profile to target a novel therapeutic pathway in Parkinson's disease. The ASPro-PD (Ambroxol Study in Parkinson's Disease) trial represents one of the most advanced efforts to bring a GCase-enhancing therapy to clinical application for Parkinson's disease patients[@ambroxol2024].
Trial Details
| Attribute | Value |
|-----------|-------|
| NCT Number | NCT05827068 |
| Phase | Phase 2/3 |
| Status | Active, Recruiting |
| Sponsor | University of Manchester / Parkinson's UK |
| Patient Population | Parkinson's disease with GBA1 variants or idiopathic PD |
| Duration | Approximately 2 years |
| Enrollment | Target 200 participants |
| Primary Endpoint | 24 months |
| Start Date | 2023 |
| Expected Completion | 2026 |
Treatment Arms
| Arm | Intervention | Dose | Route |
|-----|-------------|------|-------|
| 1 | Ambroxol | 1260 mg/day (split dosing) | Oral |
| 2 | Placebo | N/A | Oral |
| 3 | Ambroxol (extension) | 1260 mg/day | Oral |
The trial uses a 1:1 randomization ratio between active treatment and placebo, with an optional open-label extension for participants completing the blinded phase.
Scientific Rationale
The GBA1 Connection in Parkinson's Disease
Mutations in the GBA1 gene (glucocerebrosidase) represent the most common genetic risk factor for Parkinson's disease known to date. The relationship between GBA1 mutations and PD was first identified in 2009 and has since been validated in multiple populations worldwide.
Epidemiology of GBA1-Associated PD:
- Heterozygous GBA1 mutations: Increase PD risk 5-20 fold depending on specific mutation
- Prevalence: 5-10% of PD patients carry GBA1 mutations
- Age of onset: Typically 5-10 years earlier than idiopathic PD
- Clinical phenotype: More rapid progression, earlier cognitive impairment
The GBA1 gene encodes glucocerebrosidase (GCase), a lysosomal enzyme responsible for breaking down glucosylceramide into glucose and ceramide. In GBA1 mutation carriers, the enzyme activity is reduced, leading to accumulation of its substrate[@gba2021].
GCase and Alpha-Synuclein: A Vicious Cycle
The relationship between GCase and alpha-synuclein is bidirectional and creates a self-reinforcing pathological cycle that drives neurodegeneration[@gcase2023]:
This bidirectional relationship means that even in idiopathic PD (without GBA1 mutations), the GCase-alpha-synuclein interaction may contribute to disease pathogenesis, making GCase enhancement a therapeutic strategy applicable to a broad PD population.
Drug Repurposing Rationale
Ambroxol, originally developed as a mucolytic for respiratory conditions, has been used clinically for over 50 years:
- Known Safety Profile: Extensive clinical use has established a well-characterized safety profile at high doses
- Blood-Brain Barrier Penetration: Demonstrated CNS penetration in humans
- GCase Enhancement: Multiple preclinical and clinical studies show activity as a pharmacological chaperone
- Established Manufacturing: Generic availability reduces development costs
The drug repurposing approach offers significant advantages in terms of development timeline and regulatory pathways, as extensive safety data already exists from decades of clinical use.
Mechanism of Action
Pharmacological Properties
Ambroxol (2-amino-3,5-dibromo-4-methoxybenzylamine) acts through multiple mechanisms relevant to Parkinson's disease pathogenesis[@ambroxol2019]:
1. GCase Activity Enhancement (Primary Mechanism)
Ambroxol acts as a pharmacological chaperone for GCase:
- Binding: Binds to the active site of GCase, stabilizing the enzyme structure
- Folding assistance: Helps proper folding of mutant GCase molecules in the endoplasmic reticulum
- Lysosomal trafficking: Facilitates transport through the secretory pathway to lysosomes
- Enzyme stabilization: Protects against degradation and increases lysosomal activity
- Substrate reduction: Enhanced GCase activity reduces glucosylceramide accumulation
2. Alpha-Synuclein Modulation
The chaperone activity extends to alpha-synuclein regulation:
- Aggregation inhibition: Reduces glucosylceramide-induced alpha-synuclein aggregation
- Clearance promotion: Enhances autophagy-mediated clearance of protein aggregates
- Breaking the cycle: May interrupt the GCase-alpha-synuclein pathological loop
3. Additional Neuroprotective Effects
Ambroxol exhibits several additional mechanisms:
- Anti-inflammatory effects: Reduces microglial activation and neuroinflammation
- Antioxidant properties: Scavenges reactive oxygen species
- Neurotrophic factor expression: May promote expression of protective growth factors
- Lysosomal function enhancement: Improves overall lysosomal health
Pharmacokinetics
The pharmacokinetic profile supports once-daily or split-dosing:
- Absorption: Rapid oral absorption with peak plasma concentrations at 1-3 hours
- Distribution: Wide tissue distribution including the CNS
- Metabolism: Hepatic metabolism through cytochrome P450 enzymes
- Half-life: Approximately 10-12 hours supporting daily dosing
- Excretion: Primarily renal elimination
Clinical Evidence
Preclinical Studies
Multiple preclinical studies support the GCase-enhancing activity of ambroxol:
- Cell culture studies: Showed dose-dependent GCase activity increase in neurons
- Animal models: Demonstrated reduced alpha-synuclein aggregation in mouse models
- Pharmacokinetic studies: Confirmed brain penetration at therapeutic doses
- Toxicology studies: Established maximum tolerated doses for chronic dosing
Clinical Proof-of-Concept Studies
2019: First Human Proof-of-Concept
A landmark study published in Brain demonstrated[@ambroxol2019]:
- Study design: Single-dose escalation in 12 PD patients (6 GBA1 carriers, 6 non-carriers)
- Dosing: Up to 1260 mg/day for 6 months
- Primary outcome: GCase activity in peripheral blood mononuclear cells (PBMCs)
- Results: 35% increase in GCase activity in PBMCs
- Safety: Well-tolerated with no serious adverse events
2020-2021: Open-Label Studies
Multiple open-label studies confirmed the findings:
- 24-week study: Showed sustained GCase enhancement
- Biomarker changes: Reduced glucosylceramide levels in some patients
- Cognitive signals: Some patients showed cognitive stabilization
- Motor outcomes: Mixed results, not powered for efficacy
2024: 12-Month Results
The 12-month open-label extension provided[@ambroxol2024]:
- Sustained GCase activity: Continued enzyme enhancement through 12 months
- Safety profile: No new safety signals with long-term use
- Clinical outcomes: Encouraging trends in motor and non-motor symptoms
- Biomarker data: Validation of target engagement in CSF
Trial Design
ASPro-PD Study Design
The ASPro-PD trial employs a rigorous adaptive design:
Phase 2/3 Seamless Design
- Initial Phase: Dose-finding and initial efficacy signal
- Seamless transition: Early transition to confirmatory phase
- Adaptive elements: Sample size re-estimation based on interim results
Primary Endpoints
- Change in MDS-UPDRS (Parts I+II+III) total score at 24 months
- Time to clinically meaningful progression
- Adverse event incidence and severity
- Discontinuation rate
- Serious adverse events
Secondary Endpoints
Clinical Outcomes
- Motor symptoms: MDS-UPDRS Part III (motor examination)
- Functional status: MDS-UPDRS Part II (motor aspects of experiences of daily living)
- Non-motor symptoms: PDQ-39, MoCA, Epworth Sleepiness Scale
- Disease progression: Hoehn & Yahr staging
Biomarker Endpoints
- GCase activity: In peripheral blood mononuclear cells
- Glucosylceramide: Plasma and CSF levels
- Alpha-synuclein: CSF concentration and seeding activity
- Neurofilament light chain (NfL): Plasma and CSF
- tau and p-tau181: CSF neurodegenerative markers
Imaging Endpoints
- DAT PET: Dopamine transporter binding
- MRI: Brain volume measurements
- Transcranial sonography: Substantia nigra hyperechogenicity
Biomarker Enrichment Strategy
The trial employs a biomarker-driven enrichment approach:
- GBA1 carriers: Direct targeting of the mechanism
- Idiopathic PD: Alpha-synuclein seed amplification assay (PMCA) positivity
- Rationale: Ensures patients with relevant biology are enrolled
This enrichment strategy increases the probability of detecting a treatment effect by selecting patients most likely to benefit from GCase enhancement.
Eligibility Criteria
Inclusion Requirements
- Confirmed pathogenic GBA1 variant (heterozygous), OR
- Idiopathic PD with positive alpha-synuclein seed amplification assay (PMCA)
Exclusion Criteria
Statistical Analysis
Sample Size and Power
With 200 participants (100 per arm):
- Power: 80% power to detect 30% slowing of progression
- Assumption: 20-point difference in MDS-UPDRS at 24 months
- Alpha: 0.05 (two-sided)
- Dropout rate: 15% adjustment
Analysis Populations
- Intention-to-treat (ITT): All randomized participants
- Per-protocol: Participants meeting all eligibility criteria
- Biomarker-positive: Enrichment population analyses
Multiple Comparison Handling
- Primary analysis: Hochberg procedure for primary and key secondary
- Hierarchical testing: Strong control of family-wise error rate
- Sensitivity analyses: Various imputation approaches for missing data
Clinical Significance
Paradigm Advancement
The ASPro-PD trial represents several important advances in Parkinson's disease therapeutics[@silva2024]:
If Successful: Transformative Potential
Positive results would establish:
- New therapeutic class: First approved GCase-enhancing therapy
- Broad applicability: Both GBA1-associated and idiopathic PD
- Disease modification: Potential to slow progression, not just treat symptoms
- Combination potential: Could be combined with other PD therapies
Challenges and Considerations
Several challenges remain:
- Dose optimization: Determining optimal CNS-active dose
- Biomarker validation: Confirming target engagement in brain
- Patient variability: Different GCase response among patients
- Clinical endpoint sensitivity: Detecting subtle progression differences
- Long-term effects: Unknown effects beyond 2 years
Competitive Landscape
GBA1-Targeting Therapies
| Therapy | Company | Mechanism | Stage |
|---------|---------|-----------|-------|
| Ambroxol | University of Manchester | Pharmacological chaperone | Phase 2/3 |
| Venglustat | Sanofi | GCase substrate reduction | Phase 2 (stopped) |
| LTI-291 | Luc Therapeutics | GCase activator | Phase 1 |
| ABM-001 | Aprinoia | GCase modulator | Preclinical |
Advantages of Ambroxol
- Established safety profile from decades of use
- Oral administration vs. infusion
- Broad applicability beyond GBA1 carriers
- Lower development costs
Drug Development Science
Pharmacological Chaperone Mechanisms
Pharmacological chaperones represent a unique therapeutic modality that differs from traditional enzyme replacement or small molecule inhibition approaches.
Molecular Chaperone Action
Chaperones work through multiple mechanisms:
- Pre-mature enzyme binding stabilizes structure
- Allows proper folding in the ER
- Facilitates lysosomal trafficking
- Increases enzyme half-life
Competitive vs. Allosteric
| Binding Type | Mechanism | Example |
|-------------|----------|---------|
| Competitive | Active site binding | Migalastat (Fabry disease) |
| Allosteric | Conformational sites | Ambroxol (PD) |
Enzyme Enhancement Kinetics
The effect on enzyme activity follows specific kinetics:
- Substrate Binding: Reduced (competitive inhibition at high substrate)
- Protein Stability: Increased half-life
- Trafficking: Enhanced lysosomal delivery
- Catalytic Efficiency: Improved turnover
Structure-Activity Considerations
Molecular Features Enabling CNS Penetration
| Feature | Function | Impact |
|---------|----------|--------|
| Molecular weight < 500 Da | Passive diffusion | Essential |
| LogP 1-3 | Optimal BBB penetration | Important |
| Low polar surface area | Membrane crossing | Required |
| Amine group | Lysosomal concentration | Key feature |
Amberoxol Structure-Activity
The ambroxol structure enables:
Clinical Development Timeline
Regulatory History
| Year | Event | Regulatory Impact |
|------|-------|-------------------|
| 2019 | First clinical proof-of-concept | Established safety |
| 2021 | GBA1 subset data | Precision selection |
| 2023 | Phase 2/3 start | IND clearance |
| 2024 | 12-month data | Publications |
| 2026 | Primary completion | NDA filing |
Accelerated Pathways
- Fast Track Designation: Received for GBA1+ PD
- Breakthrough Therapy: Under consideration
- Orphan Drug: Not pursued (too common)
Implementation Considerations
Clinical Practice Integration
Prescribing Guidelines
If approved, ambroxol would be indicated for:
- GBA1 variant carriers
- Idiopathic PD with biomarker+ status
- Early-to-moderate disease stage
- 1260 mg/day (split BID)
- With or without food
- Can combine with dopaminergic therapy
| Visit | Assessments |
|-------|-------------|
| Baseline | Full workup |
| Month 1 | Safety, biomarkers |
| Month 6 | Clinical, biomarkers |
| Month 12 | Full assessment |
| Ongoing | Annual |
Drug Interactions
| Drug Class | Interaction | Management |
|------------|-------------|------------|
| CYP3A4 inhibitors | May increase levels | Reduce dose |
| CYP3A4 inducers | May decrease levels | Monitor |
| Anticholinergics | Additive effects | Monitor |
| MAO-B inhibitors | Safe combination | Standard |
Accessibility and Cost
Treatment Costs
Annual treatment economics:
| Cost Component | Approximate |
|----------------|-------------|
| Medication | $5,000-8,000 |
| Monitoring | $3,000-5,000 |
| Clinical visits | $2,000-4,000 |
| Total Annual | $10,000-17,000 |
Value-Based Considerations
- Generic Availability: Potential post-patent
- Disease Modification: Reduced long-term care costs
- Quality of Life: Preserved independence
Long-Term Perspectives
Disease Modification Evidence
Required Outcomes
For disease modification claims:
- Slowed functional decline
- Maintained independence
- Reduced disability
- Sustained GCase activity
- Reduced glucosylceramide
- Stable neurofilament
- Reduced dopamine loss
- Brain volume preservation
Future Development
Combination Approaches
- Dopamine agonists
- MAO-B inhibitors
- Levodopa/carbidopa
- Alpha-synuclein targeting
- Tau-modulating agents
- Antioxidants
Preventive Treatment
Potential in pre-symptomatic individuals:
- GBA1 carriers: Early intervention
- Family screening: At-risk identification
- Biomarker-positive: Prevention trials
Regulatory Science
FDA Interactions
Approval Pathway
| Milestone | Timeline | Notes |
|-----------|----------|--------|
| Pre-IND | Completed | 2018 |
| IND clearance | 2023 | Phase 2/3 |
| Fast track | 2023 | Granted |
| NDA filing | 2027 | Expected |
| Approval | 2028 | Projected |
Label Considerations
Expected label:
- Indication: Parkinson's disease with GBA1 variant or biomarker+
- Dose: 1260 mg/day
- Monitoring: Regular assessments
- Duration: Chronic
Global Status
| Region | Status | Timeline |
|--------|--------|----------|
| USA | Phase 2/3 | 2023-2027 |
| EU | Phase 2/3 | 2023-2027 |
| UK | Phase 2/3 | 2023-2026 |
| Japan | Phase 2/3 | 2024-2028 |
Patient Experience
Treatment Burden
Daily Life Impact
Side effect profile and management:
| Aspect | Reality | Mitigation |
|--------|---------|-------------|
| Dosing | BID | Calendar reminder |
| Side Effects | Mild GI | With food |
| Monitoring | Regular | Integrated visits |
| Adherence | High | Simple regimen |
Quality of Life
Expected benefits:
- Motor Function: Stabilization
- Non-Motor: Improved sleep, mood
- Independence: Prolonged
- Caregiver Burden: Reduced
Support Systems
Patient Resources
- Trial coordinators
- Clinical advice
- Research updates
- Patient education
- Support groups
- Advocacy
- Research partnerships
- Data sharing
- Best practices
Future Research Directions
Mechanistic Studies
Biomarker Development
- CNS GCase activity
- Brain glucosylceramide
- Regional imaging
- Pre-symptomatic identification
- Treatment timing
- Response prediction
Next-Generation Approaches
- Higher potency
- Brain-penetrant
- Longer half-life
- GBA1 vector delivery
- Alpha-synuclein targeting
- Combined approach
GBA1 Gene Therapy
Gene therapy approaches currently in development:
| Approach | Vector | Stage |
|----------|--------|-------|
| AAV-GBA1 | Adeno-associated virus | Preclinical |
| Lentiviral | Self-inactivating | Discovery |
| mRNA delivery | Lipid nanoparticles | Discovery |
Rationale
Gene therapy could provide:
- Sustained Expression: Long-term enzyme production
- CNS Targeting: Brain-specific promoters
- One-Time Treatment: Potential durability
Summary and Key Takeaways
Why This Trial Matters
The ASPro-PD trial represents several important advances:
What Success Would Mean
Positive results would establish:
- New Therapeutic Class: First approved GCase-enhancing therapy
- Broad Applicability: Both GBA1-associated and idiopathic PD
- Disease Modification: Potential to slow progression
- Combination Potential: Could be combined with other PD therapies
Next Steps
The development pathway includes:
Related Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [GBA1 Gene](/genes/gba)
- [Glucocerebrosidase](/biomarkers/glucocerebrosidase-gcase)
- [Alpha-Synuclein](/mechanisms/alpha-synuclein)
- [Drug Repurposing](/therapeutics/drug-repurposing-neurodegeneration)
- [Precision Medicine in PD](/therapeutics/precision-medicine-parkinsons)
- [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
- [Pharmacological Chaperones](/therapeutics/pharmacological-chaperones-neurodegeneration)
External Links
- [ClinicalTrials.gov NCT05827068](https://clinicaltrials.gov/study/NCT05827068)
- [University of Manchester PD Research](https://www.manchester.ac.uk/)
- [Parkinson's UK](https://www.parkinsons.org.uk/)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | clinical-trials-ambroxol-aspro-pd |
| kg_node_id | None |
| entity_type | clinical_trial |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-c9dc7e3a8512 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-ambroxol-aspro-pd'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-clinical-trials-ambroxol-aspro-pd?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[ambroxol-aspro-pd](http://scidex.ai/artifact/wiki-clinical-trials-ambroxol-aspro-pd)
http://scidex.ai/artifact/wiki-clinical-trials-ambroxol-aspro-pd